

# Jesmin Shafiq

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3858851/publications.pdf>

Version: 2024-02-01

34  
papers

1,700  
citations

643344

15  
h-index

425179

34  
g-index

34  
all docs

34  
docs citations

34  
times ranked

2403  
citing authors

#	ARTICLE	IF	CITATIONS
1	Surgical and radiotherapy patterns of care in the management of breast cancer in NSW and ACT Australia. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2022, 66, 442-454.	0.9	6
2	Predicting 2-year survival in stage I-III non-small cell lung cancer: the development and validation of a scoring system from an Australian cohort. <i>Radiation Oncology</i> , 2022, 17, 74.	1.2	3
3	Radiotherapy service need in the Pacific Island countries. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, e217-e225.	0.7	4
4	Patterns of use of palliative radiotherapy fractionation for bone metastases and 30-day mortality. <i>Radiotherapy and Oncology</i> , 2021, 154, 299-305.	0.3	8
5	Patterns of palliative radiotherapy fractionation for brain metastases patients in New South Wales, Australia. <i>Radiotherapy and Oncology</i> , 2021, 156, 174-180.	0.3	6
6	Translation of oncology multidisciplinary team meeting (MDM) recommendations into clinical practice. <i>BMC Health Services Research</i> , 2021, 21, 461.	0.9	5
7	Trends in the use of short-course radiation therapy for rectal cancer in New South Wales, Australia. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2021, , .	0.9	2
8	Variation in the use of radiotherapy fractionation for breast cancer: Survival outcome and cost implications. <i>Radiotherapy and Oncology</i> , 2020, 152, 70-77.	0.3	10
9	Radiotherapy underutilisation and its impact on local control and survival in New South Wales, Australia. <i>Radiotherapy and Oncology</i> , 2019, 141, 41-47.	0.3	16
10	Estimating the cost of radiotherapy for 5-year local control and overall survival benefit. <i>Radiotherapy and Oncology</i> , 2019, 136, 154-160.	0.3	11
11	Radiotherapy patterns of care for stage I and II non-small cell lung cancer in Sydney, Australia. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2019, 63, 131-141.	0.9	5
12	The population benefit of evidence-based radiotherapy: 5-Year local control and overall survival benefits. <i>Radiotherapy and Oncology</i> , 2018, 126, 191-197.	0.3	71
13	Impact of radiotherapy underutilisation measured by survival shortfall, years of potential life lost and disability-adjusted life years lost in New South Wales, Australia. <i>Radiotherapy and Oncology</i> , 2018, 129, 191-195.	0.3	17
14	The Benefits of Providing External Beam Radiotherapy in Low- and Middle-income Countries. <i>Clinical Oncology</i> , 2017, 29, 72-83.	0.6	34
15	Comparison of Magnetic Resonance Imaging and Computed Tomography for Breast Target Volume Delineation in Prone and Supine Positions. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 905-912.	0.4	18
16	A Population-based Model of Local Control and Survival Benefit of Radiotherapy for Lung Cancer. <i>Clinical Oncology</i> , 2016, 28, 627-638.	0.6	28
17	Estimation of the optimal utilisation rates of radical prostatectomy, external beam radiotherapy and brachytherapy in the treatment of prostate cancer by a review of clinical practice guidelines. <i>Radiotherapy and Oncology</i> , 2016, 118, 118-121.	0.3	10
18	Estimating the Population Benefit of Radiotherapy: Using Demand Models to Estimate Achievable Cancer Outcomes. <i>Clinical Oncology</i> , 2015, 27, 99-106.	0.6	6

#	ARTICLE	IF	CITATIONS
19	The population benefit of radiotherapy for cervical cancer: Local control and survival estimates for optimally utilized radiotherapy and chemoradiation. <i>Radiotherapy and Oncology</i> , 2015, 114, 389-394.	0.3	26
20	Estimating the demand for radiotherapy from the evidence: A review of changes from 2003 to 2012. <i>Radiotherapy and Oncology</i> , 2014, 112, 140-144.	0.3	387
21	A comparison of systemic breast cancer therapy utilization in Canada (British Columbia), Scotland (Dundee), and Australia (Western Australia) with models of "optimal" therapy. <i>Breast</i> , 2012, 21, 562-569.	0.9	8
22	A comparison of surgical and radiotherapy breast cancer therapy utilization in Canada (British) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 627. <i>Breast</i> , 2012, 21, 570-577.	0.9	14
23	Do multidisciplinary team meetings make a difference in the management of lung cancer?. <i>Cancer</i> , 2011, 117, 5112-5120.	2.0	150
24	Dosimetric implications of the addition of 18 fluorodeoxyglucose-positron emission tomography in CT-based radiotherapy planning for non-small-cell lung cancer. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2010, 54, 152-160.	0.9	6
25	Management of skin toxicity during radiation therapy: A review of the evidence. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2010, 54, 264-279.	0.9	97
26	Use of chemotherapy at end of life in oncology patients. <i>Annals of Oncology</i> , 2009, 20, 1555-1559.	0.6	137
27	The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for patients with Bone Metastases: The EORTC QLQ-BM22. <i>European Journal of Cancer</i> , 2009, 45, 1146-1152.	1.3	108
28	Patients' and health care professionals' evaluation of health-related quality of life issues in bone metastases. <i>European Journal of Cancer</i> , 2009, 45, 2510-2518.	1.3	50
29	An international review of patient safety measures in radiotherapy practice. <i>Radiotherapy and Oncology</i> , 2009, 92, 15-21.	0.3	113
30	Establishing treatment benchmarks for mammography-screened breast cancer population based on a review of evidence-based clinical guidelines. <i>Cancer</i> , 2008, 112, 1912-1922.	2.0	11
31	An evidence-based estimation of local control and survival benefit of radiotherapy for breast cancer. <i>Radiotherapy and Oncology</i> , 2007, 84, 11-17.	0.3	26
32	Role of radiotherapy in cancer control in low-income and middle-income countries. <i>Lancet Oncology</i> , The, 2006, 7, 584-595.	5.1	249
33	Radiotherapy might not be the answer in Africa " Authors' reply. <i>Lancet Oncology</i> , The, 2006, 7, 705-706.	5.1	1
34	Mechanisms of vasodilation induced by NKH477, a water-soluble forskolin derivative, in smooth muscle of the porcine coronary artery.. <i>Circulation Research</i> , 1992, 71, 70-81.	2.0	57